Min-Han Tan, Founder and CEO of Lucence, shared a post on LinkedIn by Mayo Clinic Laboratories, adding:
“ctDNA and ctRNA liquid biopsy is available now to help US cancer patients to help identify guideline recommended biomarkers.
LiquidHallmark ctDNA and ctRNA is the first such Medicare fully reimbursed test.
Very grateful to help advance liquid biopsy together with Mayo Clinic Laboratories!”
Quoting Mayo Clinic Laboratories’ post:
“Liquid biopsy cancer testing is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
Learn about patients who will benefit from the test and how an oncologist might use the results.”
Watch the video attached to this post.
More posts featuring Min-Han Tan on OncoDaily.